Ganymed Robotics Announces Appointment of Seasoned Leadership Team to Bring to Market Its Next Generation Surgical Technology
3.10.2023 09:30:00 EEST | Business Wire | Press release
Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, is happy to announce a series of senior leadership appointments to drive the company’s growth as it prepares for industrialization and commercial launch. The firm has appointed 5 seasoned executives to lead strategic and operational developments across all key functions, ranging from product development to regulatory and market access, finance, human resources and legal. Former companies include ZimmerBiomet, Alphatec, EOS Imaging, Corwave, Beckton Dickinson, Robocath, Médecins Sans Frontières.
The composition of the new Executive Committee exhibits strong expertise in both launching innovative medical devices and scaling medtech companies, as well as gender parity. It is composed of 8 members : Sophie Cahen, CEO and co-founder, Silvère Lucquin, Chief Operating Officer, and Michel Vernizeau, VP R&D, and 5 seasoned new members: Lukas Vancura as VP Product Marketing, Clémentine Liard as VP Quality Assurance and Regulatory Affairs (QARA), Sandra Demol as Human Resources Director, Julien Puaux as VP Finance and Juliette Loget as General Counsel. These additions to the Executive Committee reflect Ganymed’s continued attractiveness for talents of all seniority, and its commitment to bringing its game-changing arthroplasty robot into operating rooms as quickly as possible.
“I am delighted to partner with such talented senior executives who bring to the company their impressive experience and recognized expertise, as we accelerate the development of our revolutionary patented technology platform and prepare for industrialization and launch of our first surgical robotic assistant for knee arthroplasty,” says Sophie Cahen. “The arrival of the leadership team’s newest members is a testimony of the swift growth that Ganymed accomplished over the past 18 months, both on the scientific and operational fronts, and speaks to a team united by a profound sense of shared purpose.”
Ganymed Robotics’ ambition is to democratize access to quality care in hard tissue surgery. The company aims to secure and standardize a complex surgical gesture, so that each patient gets the right, personalized care. The first application is a co-manipulated surgical robotic assistant for total knee arthroplasty (TKA). It has developed a proprietary technology platform built around two disruptive innovations: contactless localization of the bones and human-machine collaborative movement.
Over the past 18 months, Ganymed reached several major milestones, attesting of its ability to efficiently implement its growth strategy: it completed a 36 M€ Series B fundraising round with a high-profile group of healthcare investors, welcomed two world renowned independent members on its Board of Directors, Michel Therin et Mike Lobinsky, doubled the size of its team across all functions to reach 40 persons today, secured strategic partnerships, moved forward with regulatory and marketing developments, won new national and international innovation awards, and ran successful pre-clinical tests. With the arrival of high-profile senior executives on its leadership team, Ganymed is ideally positioned to successfully accelerate the execution of its strategic, industrial, and operational development plan.
About Ganymed Robotics
Ganymed Robotics is a medical device company founded in 2018, developing the next generation of robotic assistance technologies for orthopedic surgery. The company’s mission is to improve patient outcome, surgeon experience, and overall efficiency of care delivery for its target indications. Based in Paris, Ganymed Robotics currently employs 40 people who develop a proprietary technology platform combining computer vision, a branch of artificial intelligence, and mechatronics, in close collaboration with world-class clinicians and advisors. The first application is a robotic surgical assistant for knee arthroplasties, a common and fast-growing intervention associated with high dissatisfaction rates of above 20%. Ganymed Robotics intends to progressively deploy its technology to address several other orthopedics indications. Ganymed Robotics won national and international innovation awards, such as I-Nov, I-Lab, French Tech DeepNum20, French Tech Emergence, Deep Tech Pioneer, EIT Health, Wilco, EIC Accelerator. For more information: www.ganymedrobotics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231002032667/en/
Contact information
Press
Strategies & Image (S&I)
Anne Rein
+33 6 03 35 92 05
anne.rein@strategiesimage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GenBio AI Builds First World Model of the Human Cell18.8.2026 16:00:00 EEST | Press release
GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by various research labs, AIDO Cell is the first to integrate the entire molecular-to-cellular spectrum into one continuous simulation. Using the system
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 16:00:00 EEST | Press release
Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance. Verified creators, less guesswork. Automated anti-fraud vetting and identity verification at payout means developers partner with rea
KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 15:48:00 EEST | Press release
The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCCA) The standout feature of this year’s joint pavilion is its overwhelming genre diversity. The lineup includes roguelike deckbuilders, visual novels, 2D shooters, rhythm action, and cooperative horror survival—catering to a broad spectrum of gamers—alongside immersive content that integrates AI and XR technology. Introducing the Participating T
SLB to Support Offshore Production Restoration for Brunei Shell Petroleum18.8.2026 15:06:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded a contract by Brunei Shell Petroleum (BSP) to support production restoration from shut-in wells across multiple offshore fields. The contract scope spans subsurface evaluation, well candidate selection, engineering and offshore execution. Project management, intervention services, monitoring, metering and marine logistics are integrated within a single coordinated execution model designed to support efficient production restoration. “Building on our long collaboration in the region, this contract reflects a shared commitment to maximizing value from existing offshore resources,” said Gokhan Yarim, senior vice president of Integration, SLB. “Together with BSP, we are combining SLB’s production expertise and integrated execution capabilities to help restore production from shut-in wells, increase recovery from existing infrastructure and support BSP’s long-term production objectives.” The project marks t
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and Nepal, exceeding the program’s original scope by approximately 150 patients and helping establish access to innovative cancer care for patients who previo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
